Salvage Radiotherapy Versus Observation for Biochemical Recurrence Following Radical Prostatectomy for Prostate Cancer: A Matched Pair Analysis

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2022 Feb 15

PMID 35159007

Authors

Derya Tilki

Felix Preisser

Reinhard Thamm

Raisa S Pompe

Felix K-H Chun

Markus Graefen

Alessandra Siegmann

Dirk Bohmer

Volker Budach

Thomas Wiegel

Affiliations

Soon will be listed here.

Abstract

Background: Salvage radiotherapy (SRT) improves oncologic outcomes in prostate cancer (PCa) patients who develop biochemical recurrence (BCR) after radical prostatectomy (RP). However, evidence on hard clinical endpoints is scarce. We compare long-term oncologic outcomes of SRT versus no radiotherapy (noRT) in patients with BCR after RP.

Patients And Methods: Within a multi-institutional database, we identified patients with BCR after RP between 1989 and 2016 for PCa. Patients with lymph node invasion, with adjuvant radiotherapy, or with additional androgen deprivation therapy at BCR were excluded. In all patients with SRT, SRT was delivered to the prostatic bed only. Propensity score matching (PSM) was performed to account for differences in pathologic tumor characteristics. Kaplan-Meier analyses and Cox regression models tested the effect of SRT versus no RT on metastasis-free (MFS) and overall survival (OS).

Results: Of 1832 patients with BCR, 32.9% = 603) received SRT without ADT. The median follow-up was 95.9 months. Median total SRT dose was 70.2 Gy. After 1:1 PSM, at 15 years after RP, MFS and OS rates were 84.3 versus 76.9% ( < 0.001) and 85.3 versus 74.4% ( = 0.04) for SRT and noRT, respectively. In multivariable Cox regression models, SRT was an independent predictor for metastasis (HR: 0.37, < 0.001) and OS (HR: 0.64, = 0.03).

Conclusion: This is the first matched-pair analysis investigating the impact of SRT versus observation only in post-RP recurrent PCa. After compensating for established risk factors, SRT was associated with better long-term MFS and OS. These results on clinical endpoints underline the curative potential of SRT.

Citing Articles

Salvage Radiotherapy for Relapsed Prostate Cancer after Radical Prostatectomy Is Associated with Normal Life Expectancy.

Lohm G, Knornschild F, Neumann K, Budach V, Schwartz S, Burock S Cancers (Basel). 2024; 16(3).

PMID: 38339285 PMC: 10854858. DOI: 10.3390/cancers16030534.

References

Pfister D, Bolla M, Briganti A, Carroll P, Cozzarini C, Joniau S . Early salvage radiotherapy following radical prostatectomy. Eur Urol. 2013; 65(6):1034-43. DOI: 10.1016/j.eururo.2013.08.013. View

Cotter S, Chen M, Moul J, Lee W, Koontz B, Anscher M . Salvage radiation in men after prostate-specific antigen failure and the risk of death. Cancer. 2011; 117(17):3925-32. DOI: 10.1002/cncr.25993. View

Pompe R, Gild P, Karakiewicz P, Bock L, Schlomm T, Steuber T . Long-term cancer control outcomes in patients with biochemical recurrence and the impact of time from radical prostatectomy to biochemical recurrence. Prostate. 2018; 78(9):676-681. DOI: 10.1002/pros.23511. View

Preisser F, Chun F, Pompe R, Heinze A, Salomon G, Graefen M . Persistent Prostate-Specific Antigen After Radical Prostatectomy and Its Impact on Oncologic Outcomes. Eur Urol. 2019; 76(1):106-114. DOI: 10.1016/j.eururo.2019.01.048. View

Preisser F, van den Bergh R, Gandaglia G, Ost P, Surcel C, Sooriakumaran P . Effect of Extended Pelvic Lymph Node Dissection on Oncologic Outcomes in Patients with D'Amico Intermediate and High Risk Prostate Cancer Treated with Radical Prostatectomy: A Multi-Institutional Study. J Urol. 2019; 203(2):338-343. DOI: 10.1097/JU.0000000000000504. View

Cornford P, van den Bergh R, Briers E, Van den Broeck T, Cumberbatch M, De Santis M . EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part II-2020 Update: Treatment of Relapsing and Metastatic Prostate Cancer. Eur Urol. 2020; 79(2):263-282. DOI: 10.1016/j.eururo.2020.09.046. View

Jairath N, Dal Pra A, Vince Jr R, Dess R, Jackson W, Tosoian J . A Systematic Review of the Evidence for the Decipher Genomic Classifier in Prostate Cancer. Eur Urol. 2020; 79(3):374-383. DOI: 10.1016/j.eururo.2020.11.021. View

Markowski M, Chen Y, Feng Z, Cullen J, Trock B, Suzman D . PSA Doubling Time and Absolute PSA Predict Metastasis-free Survival in Men With Biochemically Recurrent Prostate Cancer After Radical Prostatectomy. Clin Genitourin Cancer. 2019; 17(6):470-475.e1. PMC: 9774681. DOI: 10.1016/j.clgc.2019.08.002. View

Bandini M, Marchioni M, Preisser F, Zaffuto E, Tian Z, Tilki D . Survival after radical prostatectomy or radiotherapy for locally advanced (cT3) prostate cancer. World J Urol. 2018; 36(9):1399-1407. DOI: 10.1007/s00345-018-2310-y. View

10.

Bartkowiak D, Siegmann A, Bohmer D, Budach V, Wiegel T . The impact of prostate-specific antigen persistence after radical prostatectomy on the efficacy of salvage radiotherapy in patients with primary N0 prostate cancer. BJU Int. 2019; 124(5):785-791. DOI: 10.1111/bju.14851. View

11.

Grivas N, de Bruin D, Barwari K, van Muilekom E, Tillier C, van Leeuwen P . Ultrasensitive prostate-specific antigen level as a predictor of biochemical progression after robot-assisted radical prostatectomy: Towards risk adapted follow-up. J Clin Lab Anal. 2018; 33(2):e22693. PMC: 6818553. DOI: 10.1002/jcla.22693. View

12.

Antonarakis E, Feng Z, Trock B, Humphreys E, Carducci M, Partin A . The natural history of metastatic progression in men with prostate-specific antigen recurrence after radical prostatectomy: long-term follow-up. BJU Int. 2011; 109(1):32-9. PMC: 3204323. DOI: 10.1111/j.1464-410X.2011.10422.x. View

13.

Siegmann A, Bottke D, Faehndrich J, Brachert M, Lohm G, Miller K . Salvage radiotherapy after prostatectomy - what is the best time to treat?. Radiother Oncol. 2011; 103(2):239-43. DOI: 10.1016/j.radonc.2011.10.024. View

14.

Broggi G, Lo Giudice A, DI Mauro M, Asmundo M, Pricoco E, Piombino E . SRSF-1 and microvessel density immunohistochemical analysis by semi-automated tissue microarray in prostate cancer patients with diabetes (DIAMOND study). Prostate. 2021; 81(12):882-892. PMC: 8362056. DOI: 10.1002/pros.24185. View

15.

Trock B, Han M, Freedland S, Humphreys E, DeWeese T, Partin A . Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy. JAMA. 2008; 299(23):2760-9. PMC: 3076799. DOI: 10.1001/jama.299.23.2760. View

16.

Vale C, Fisher D, Kneebone A, Parker C, Pearse M, Richaud P . Adjuvant or early salvage radiotherapy for the treatment of localised and locally advanced prostate cancer: a prospectively planned systematic review and meta-analysis of aggregate data. Lancet. 2020; 396(10260):1422-1431. PMC: 7611137. DOI: 10.1016/S0140-6736(20)31952-8. View

17.

Stish B, Pisansky T, Harmsen W, Davis B, Tzou K, Choo R . Improved Metastasis-Free and Survival Outcomes With Early Salvage Radiotherapy in Men With Detectable Prostate-Specific Antigen After Prostatectomy for Prostate Cancer. J Clin Oncol. 2016; 34(32):3864-3871. DOI: 10.1200/JCO.2016.68.3425. View

18.

Tendulkar R, Agrawal S, Gao T, Efstathiou J, Pisansky T, Michalski J . Contemporary Update of a Multi-Institutional Predictive Nomogram for Salvage Radiotherapy After Radical Prostatectomy. J Clin Oncol. 2016; 34(30):3648-3654. DOI: 10.1200/JCO.2016.67.9647. View

19.

Preisser F, Bandini M, Mazzone E, Nazzani S, Marchioni M, Tian Z . Validation of the Social Security Administration Life Tables (2004-2014) in Localized Prostate Cancer Patients within the Surveillance, Epidemiology, and End Results database. Eur Urol Focus. 2018; 5(5):807-814. DOI: 10.1016/j.euf.2018.05.006. View

20.

Jackson W, Johnson S, Feng F, Hamstra D . Salvage radiation therapy improves metastasis-free survival for clinically aggressive and indolent prostate cancer recurrences after radical prostatectomy. Am J Clin Oncol. 2013; 38(4):367-72. DOI: 10.1097/COC.0b013e31829e17db. View